cytomegalovirus disease

Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to cytomegalovirus disease: CMV


 (CMV) [si″to-meg´ah-lo-vi″rus]
any of a subfamily of host-specific herpesviruses infecting humans, monkeys, and rodents, producing unique large cells with inclusion bodies. Opportunistic infection with this virus is common in immunocompromised individuals, causing clinical illnesses such as cytomegalovirus retinitis, pneumonia, esophagitis, colitis, adrenalitis, and hepatitis. It can also cause cytomegalic inclusion disease, a variety of gastrointestinal infections, and encephalitis. Most infections are mild in immunocompetent persons, but it has been associated with a syndrome called cytomegalovirus mononucleosis.
cytomegalovirus disease cytomegalic inclusion disease.

cy·to·meg·a·lic in·clu·sion dis·ease

caused by cytomegalovirus, a member of the Herpesviridae family; the presence of inclusion bodies within the cytoplasm and nuclei of enlarged cells of various organs of newborn infants dying with jaundice, hepatomegaly, splenomegaly, purpura, thrombocytopenia, and fever; the condition also occurs, at all ages, as a complication of other diseases in which immune mechanisms are severely depressed, and has been found incidentally in salivary gland epithelium, apparently as a localized or mild infection (salivary gland virus disease).

cytomegalovirus disease

References in periodicals archive ?
Antigenemia for cytomegalovirus in renal transplantation: choosing a cutoff for the diagnosis criteria in cytomegalovirus disease.
Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant.
In patients with advanced AIDS, the same symptoms may be seen in cytomegalovirus disease, lymphoma, or disseminated M.
PREVEON, formerly referred to as adefovir dipivoxil or GS 840, is an investigational, orally-administered, once-daily, reverse transcriptase inhibitor currently being studied in a variety of late-stage clinical studies to treat human immunodeficiency virus (HIV) and prevent cytomegalovirus disease.
This designation from the EMEA adds additional momentum as we continue to develop CAMVIA for transplant-related cytomegalovirus disease.
The company is currently testing vaccines for influenza and cytomegalovirus disease in clinical trials, and expects to initiate additional trials with vaccines for colon cancer and pandemic influenza in 2007 and 2008.
ViroPharma's Phase 3 liver transplant study will compare the efficacy, safety and tolerability of prophylactic use of CAMVIA versus oral ganciclovir when administered for up to 14 weeks for the prevention of cytomegalovirus disease in recipients of orthotopic liver transplants at high risk of developing CMV disease.
Cytomegalovirus disease is an opportunistic infection caused by the cytomegalovirus, which can complicate and interfere with transplant recipients' full recovery.

Full browser ?